Ascendiant Capital Maintains Buy on HeartSciences, Lowers Price Target to $8

Benzinga Newsdesk www.benzinga.com Negative 84.2%

Neg 84.2% Neu 0% Pos 0%

Ascendiant Capital analyst Lucas Ward maintains HeartSciences (NASDAQ:HSCS) with a Buy and lowers the price target from $9.2 to $8.